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ABSTRACT 31 
Longer life expectancies have led to an increased number of neurodegenerative disease cases 32 
globally. Accurate diagnosis of this devastating disorder is of crucial importance but is still 33 
feasible only by a brain biopsy after death. An enormous amount of attention and research has 34 
been in place over the years towards the better understanding of the mechanisms, as well as the 35 
early diagnosis, of neurodegeneration. However, numerous studies have been contradictory 36 
from time to time, while new diagnostic methods are constantly developed in a tireless effort 37 
to tackle the disease. Nonetheless, there is not yet a conclusive report covering a broader range 38 
of techniques for the diagnosis of different types of dementia. In this article, we critically 39 
review current knowledge on the different hypotheses about the pathogenesis of distinct types 40 
of dementia, as well as risk factors and current diagnostic approaches in a clinical setting, 41 
including neuroimaging, cerebrospinal (CSF) and blood tests. Encouraging research results for 42 
the diagnosis and investigation of neurodegenerative disorders are also reported. Particular 43 
attention is given to the field of spectroscopy as an emerging tool to detect dementias, follow-44 
up patients and potentially monitor the patients’ response to a therapeutic approach. 45 
Spectroscopic techniques, such as infrared and Raman spectroscopy, have facilitated numerous 46 
disease-related studies, including neurodegenerative disorders, and are currently undergoing 47 
trials for clinical implementation. This review constitutes a comprehensive report with an in-48 
depth focus on promising imaging, molecular biomarker and spectroscopic tests in the field of 49 
dementive diseases. 50 
 51 
 52 
 53 
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INTRODUCTION 57 
Estimates of dementia prevalence have shown that 46.8 million people live with this 58 
condition worldwide and this is expected to reach 75 million by 2030 1. People living with 59 
dementia are under-detected in high income countries, with only 20-50% of cases being 60 
accurately diagnosed in primary care; lack of diagnosis is even more evident in low- and 61 
middle-income countries 2-4 (Fig. 1). The number of new cases of dementia every year was 62 
estimated to be over 9.9 million, implying one new case every 3.2 seconds 5. A definitive 63 
diagnosis is still only been given post-mortem, thus an accurate detection is essential for 64 
providing an early intervention and improving the lives of those affected. 65 
 66 
Figure 1: Estimation of people with dementia, in millions, in high- and low/middle-income 67 
countries. Adapted from 5. 68 
Symptoms of different dementias vary depending on the type but they all share some 69 
common characteristics, such as loss of memory and other mental abilities. Under the 70 
“umbrella” term of dementia, Alzheimer’s disease (AD) and dementia with Lewy bodies 71 
(DLB) constitute the two most common types of underlying pathology 6. Other, common types 72 
of dementia include vascular dementia (VaD), frontotemporal dementia (FTD), Parkinson’s 73 
disease dementia (PDD) and mixed dementia 7-9. The majority of the above-mentioned 74 
dementias undergo the same pathological mechanism of protein misfolding, which 75 
subsequently leads to clumps of proteins and neuronal death, with VaD being an exception as 76 
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it has a distinct mechanism than the other dementias. Brain damage in VaD patients occurs due 77 
to the lack of blood supply from bleeding, clotting or narrowing of arteries which can cause 78 
nerve cell injury or death. As AD often co-exists with VaD, signs of both syndromes are most 79 
likely to be present. Furthermore, recent work by Novarino et al. has interestingly shown that, 80 
even though it does not fall into the spectrum of dementia, motor neuron disease (MND) has 81 
common features with other neurodegenerative disorders such as AD, PD and amyotrophic 82 
lateral sclerosis (ALS) 10. This indicates that study of one neurodegenerative disease could 83 
possibly advance the understanding of others as well. 84 
A number of risk factors have been associated with the development of 85 
neurodegenerative diseases and dementia. Increasing age, family history and susceptibility 86 
genes are some of the well-known unavoidable risk factors 11-13. Numerous studies have 87 
associated neurodegeneration with a range of other risks which could be more easily managed, 88 
such as lifestyle choices (e.g., diet, exercise and alcohol intake) 14-16, environmental factors 89 
(e.g., pesticides and neurotoxic metals, such as lead, mercury, arsenic) 14, 17, education 18, 90 
gender 19, 20, Down syndrome 21, 22, head injuries 23, 24 or diabetes and cardiovascular diseases 91 
25, 26. Recent findings have suggested that some factors could actually reduce risk in PD 92 
patients, including smoking, caffeine, and urate 27. These could potentially act as 93 
neuroprotective agents and thus be beneficial for patients with early neurodegeneration. A use 94 
of these methods in clinical trials, facilitated by an accurate diagnosis with the techniques 95 
described in this paper, might be more effective at an early stage prior to significant brain 96 
damage. Current ongoing trials assessing long-term treatment with nicotine (using transdermal 97 
patches for over 60 months in early PD patients), caffeine (400 mg per day for five years) and 98 
inosine for urate elevation (using early PD patients to increase serum urate concentration within 99 
24 months) aim to conclude whether these factors could facilitate therapeutic intervention or 100 
secondary prevention. 101 
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It is most likely that the majority of neurodegenerative disorders occur as a result of 102 
complex interactions between any or all the above risk factors; this renders them complicated 103 
and difficult to study. The complexity of dementia is further demonstrated by the fact that drugs 104 
aiming to improve cognitive functions and delay the deterioration, such as cholinesterase 105 
inhibitors, still remain ineffective 28, 29. Much effort has been put on clinical trials, over the 106 
years, to help treat people experiencing dementia but without much success 30, 31. It is 107 
increasingly thought that drugs should be administered at an early, pre-symptomatic stage of 108 
dementia in order to provide successful treatment. However, there is yet no robust way to pre-109 
clinically detect people who will develop dementia, which renders the need of early biomarkers 110 
crucial. 111 
Research in the field of neurodegeneration and dementias currently undergoes fast 112 
progress. Promising results from recent studies have led to a wide consensus that dementia is 113 
a slowly progressive disease which means that a diagnosis may be feasible years before 114 
symptoms develop. An early diagnosis with biological markers would greatly facilitate and 115 
accelerate the development of effective drugs and/or allow the diagnosed individuals to make 116 
better lifestyle choices. However, different research groups have employed different diagnostic 117 
approaches and studied a range of diagnostic and/or prognostic biomarkers, thus causing 118 
controversy and debate regarding the optimal method to take forward. This review will present 119 
and evaluate current knowledge with regard to a number of different dementias, including both 120 
‘traditional’ and novel diagnostic approaches. 121 
EPIDEMIOLOGY 122 
The types of dementia that will be studied in more detail in this critical review include 123 
AD, DLB, FTD, VaD, PDD and mixed dementia. 124 
Alzheimer’s disease (AD) 125 
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AD is the most common cause of dementia accounting for 60-80% of the cases. 126 
Previous estimates have shown that ~34 million people worldwide have AD, with the 127 
prevalence expected to triple by 2050 32. Determining the age of onset and defining a disease-128 
free cohort have been two of the reasons that incidence rates for AD are difficult to calculate. 129 
After bringing together data from 24 published studies, Mayeux and Stern reported an 130 
approximate incidence of 0.5% per year for the age cohort 65-70 years which increased to 6-131 
8% for the individuals over 85 years of age (Fig. 2) 33. 132 
 133 
Figure 2: Annual incidence rate (per 100 person-years) for Alzheimer’s disease. The graph 134 
illustrates an estimate of data from 24 published studies. Adapted from 33. With permission 135 
from Cold Spring Harbor Laboratory Press. 136 
The terminology of AD has been revised in the 2011 guidelines (after almost 30 years 137 
from the original criteria) to also include cases from the time point of the initial pathologic 138 
changes in the brain; in other words, before symptoms of memory loss incur 34.  Three different 139 
stages were suggested to characterise the disease according to its progression: preclinical (or 140 
pre-symptomatic) AD; mild cognitive impairment (MCI) due to AD; and dementia due to AD 141 
(Fig. 3). In a preclinical stage, the key biological changes are under way but without presenting 142 
any obvious, clinical symptoms; this primary phase is thought to begin years in advance. MCI 143 
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includes some changes in memory and thinking that can be noticeable but do not affect the 144 
ability for daily tasks; more importantly, not all people with MCI develop AD dementia 145 
eventually. In a meta-analysis of 41 cohort studies, it was found that only 38% of MCI 146 
progressed to dementia during a follow-up period of 5 years 35. Finally, the last stage of AD 147 
due to dementia includes the well-known symptoms of memory loss as well as cognitive and 148 
behavioural impairment.  149 
150 
Figure 3: Known natural history of cognitive markers implies that memory tests, which change 151 
relatively early in the disease course (1) and soon reach the maximal level of impairment (2), 152 
are useful for diagnosis at the MCI stage, but are less useful for tracking later disease 153 
progression (3). Verbal comprehension tests start to change later in the disease course: during 154 
MCI they show mild or no impairment (4), and are of limited use in diagnosis. These markers 155 
become more sensitive at the dementia stage, when the slope of change steepens (5). Adapted 156 
from 36. Reprinted by permission from: Springer Nature, Nature Reviews Neurology, The 157 
clinical use of structural MRI in Alzheimer disease, Giovanni B. Frisoni, Nick C. Fox, Clifford 158 
R. Jack Jr, Philip Scheltens, Paul M. Thompson (2010). License Number 4279300909074. 159 
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The greatest risk factor for AD is increasing age but other factors also play a significant 160 
role in developing the disease. AD can be either familial, which is inherited by a family member 161 
and is rarer, or sporadic. Family history and carrying the gene for the production of the 162 
apolipoprotein ε4 (ApoE ε4) are now well-established risk factors. ApoE is a major cholesterol 163 
carrier and has three distinct isoforms: ε2, ε3 and ε4 37. The human ApoE protein contains 299 164 
amino acids and despite the fact that the three isoforms differ by only one or two amino acids, 165 
their structure and function is entirely different 38. Individuals with two alleles of ε4 have 12-166 
fold risk to develop the disease about 10-20 years earlier than others with no ε4 alleles, whereas 167 
one ε3 allele increases the risk 3-fold. In contrast, ε2 allele decreases the risk 37, 38. Previous 168 
studies have reported the frequency of AD and mean age at clinical onset being 91% and 68 169 
years of age in ε4 homozygotes; 47% and 76 years in ε4 heterozygotes; and 20% and 84 years 170 
in ε4 non-carriers (Fig. 4)  37. Strong evidence suggests that the major mechanism by which 171 
ApoE influences AD is via its effects on Aβ metabolism 38. The toxic events of ApoE are 172 
thought to initiate when the lipoproteins bind to several cell-surface receptors to deliver lipids 173 
and to amyloid-β (Aβ) peptide; this in turn leads to synaptic dysfunction 37. Normally each 174 
ApoE isoform enhances the degradation of Aβ but ApoE ε4 seems to be less effective in Aβ 175 
clearance 37. Several mechanisms have been proposed for the role of ApoE in AD, such as 176 
promoting aggregation of Aβ or phosphorylation of tau (Fig. 5). 177 
 178 
Figure 4: Apolipoprotein ε4 (APOE ε4) as a genetic risk factor for AD. Adapted from 37. 179 
Reprinted by permission from: Springer Nature, Nature Reviews Neurology, Apolipoprotein E 180 
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and Alzheimer disease: risk, mechanisms and therapy, Chia-Chen Liu, Takahisa Kanekiyo, 181 
Huaxi Xu, Guojun Bu (2013). License Number 4279310010694. 182 
 183 
 184 
Figure 5: Proposed mechanisms for the role of apolipoprotein (ApoE) in AD pathogenesis. 185 
The major effect of ApoE isoforms on AD development is via its effect on Aβ aggregation and 186 
clearance. Other mechanisms, including the effects of ApoE isoforms on synaptic function, 187 
neurotoxicity, tau phosphorylation, and neuroinflammation, may also contribute. Independent 188 
of ApoE genotype, differences in the ApoE levels and lipidation state may also mediate 189 
processes involved in AD pathogenesis. Adapted from 38 (doi:  10.1038/nrneurol.2012.263). 190 
No changes have been made to the figure; License Number 4278980016081. 191 
 Other genetic factors that increase the risk of early-onset AD (i.e., below 65 years of 192 
age) include mutations in Amyloid Precursor Protein (APP), Presenilin 1 (PSEN1) and 193 
Presenilin 2 (PSEN2). APP is cleaved into fragments by α-, β- and γ-secretases; proteolysis by 194 
α- and γ-secretases results in non-pathogenic fragments whereas proteolysis by β- and γ-195 
secretases produces a mixture of Aβ peptides: Aβ1-40 (90%) and Aβ1-42 (10%). Aβ1-42 peptides 196 
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are more likely to aggregate and form amyloid plaques in AD patients 39. PSEN1 and PSEN2 197 
proteins are essential components of the γ-secretase; thus, mutations of PSEN1 and PSEN2 198 
result in an increased ratio Aβ1-42 / Aβ1-40, either through an increased Aβ1-42 production or 199 
decreased Aβ1-40 production, or a combination of both. However, other studies have 200 
demonstrated contradictory results showing decreased or unchanged levels of the proteins 40, 201 
41. Another study has suggested that even though they found no differences in the CSF Aβ1-42 202 
or Aβ1-40 production rate, there was an impairment of the clearance rate which subsequently led 203 
to higher levels of the protein 42. 204 
 Over the years, different mechanisms have been proposed for the pathogenesis of AD 205 
and many more are suggested as our knowledge of the disease continues to evolve 43, 44. The 206 
two main hypotheses that have prevailed though include the amyloid cascade hypothesis which 207 
leads to the aggregation of toxic Aβ oligomers, subsequently creating the extracellular Aβ 208 
plaques in the brain, and the tau hypothesis which involves hyperphosphorylation of protein 209 
tau causing aggregation and deposits in the brain as intracellular neurofibrillary tangles (NFTs) 210 
45. In a healthy brain, tau protein binds to microtubules to stabilise them with neuron cells and 211 
facilitate effective transport within the cell 46; in AD, however, tau protein becomes hyper-212 
phosphorylated which causes its detachment from the microtubules and subsequently the 213 
formation of oligomers and tangles. The theory of tau hyperphosphorylation is not universally 214 
accepted with some suggesting that post-translational modifications, other than 215 
phosphorylation, could promote the aggregation of tau; acetylation of tau, for instance, has 216 
been previously proposed to play a significant role in this 47. The initial sites and spread of 217 
neurofibrillary tangles within the brain are entirely predictable; they start in the allocortex of 218 
the medial temporal lobe (entorhinal cortex and hippocampus), then spread to the associative 219 
isocortex, sparing the primary sensory, motor and visual areas until the very end stages 48, 49. 220 
Similarly, Aβ deposition is also predictable 50, starting in the isocortical areas of the brain, then 221 
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spreading to allocortical brain regions and in the later stages to subcortical structures, including 222 
the basal ganglia and the cerebellar cortex 48. 223 
Dementia with Lewy bodies (DLB) 224 
DLB is the second most common type of dementia after AD, sharing clinical and 225 
pathological characteristics with both AD and PD. The incidence of DLB had been estimated 226 
~0.1% a year for the general population and accounts for 3.8% of new dementia cases 51, 52. 227 
The pathological hallmark of this type of dementia is the formation of characteristic clumps of 228 
proteins, called Lewy bodies (LBs). The main structural component of LBs is α-synuclein 229 
which is also found in patients with PD and multiple system atrophy (MSA), all of which are 230 
defined as synucleinopathies 53. However, LBs have also been associated with neurofibrillary 231 
tangles and Aβ plaques which are mostly present in AD. Alpha-synuclein consists of 140 amino 232 
acids and is encoded by the SNCA gene 54. Nevertheless, due to the constant and abundant Aβ42 233 
in DLB cases, it has been suggested that synucleinopathy is also promoted by APP dysfunction 234 
55. 235 
DLB and AD have many symptoms in common leading to frequent misdiagnosis. 236 
Differential diagnosis of the two subtypes of dementia is crucial to provide a more accurate 237 
prognosis, administration of the appropriate treatment and/or inclusion to a suitable clinical 238 
trial. For instance, even though DLB cases respond well to drugs prescribed to AD patients, 239 
such as cholinesterase inhibitors, they also have severe neuroleptic sensitivity reactions, which 240 
are associated with significantly increased morbidity and mortality 56. Previous work studying 241 
the survival and mortality differences between AD and DLB showed that DLB patients had 242 
increased risk of mortality with a median survival time of 78 years, which in AD was 84.6 243 
years 57. 244 
12 
 
In an effort to improve the management of this disorder, new international guidelines 245 
were very recently established 6. Clinically, DLB presents with symptoms of dementia and 246 
delirium-like alterations in cognition, attention and arousal. Other clinical symptoms, less 247 
frequent in AD, include visual hallucinations, rapid eye movement (REM) sleep behaviour 248 
disorder and Parkinsonism. Other, supportive symptoms indicating the disease are 249 
hypersomnia, presenting as excessive daytime sleepiness and hyposmia, which occurs earlier 250 
in DLB than AD cases. Imaging, genetic and fluid biomarkers have also been established for 251 
the diagnosis of DLB 6. It has also been suggested that accumulation of LB pathology starts in 252 
the brainstem, then spreads progressively to limbic regions and finally cerebral neocortex 58. 253 
Frontotemporal dementia (FTD) 254 
 Frontotemporal lobar degeneration (FTLD) is a broader term to describe three 255 
syndromes that affect the frontal and temporal lobes of the brain: frontotemporal dementia 256 
(FTD) mainly causing behavioural changes, semantic dementia (SD) mainly causing impaired 257 
word comprehension and semantic memory, and progressive non-fluent aphasia (PNFA) 258 
mainly causing impaired speech production 59, 60.  Of those, FTD, or else Pick’s disease, is the 259 
most common clinical phenotype; it is thought to be third after AD and DLB, with a prevalence 260 
ranging from 3% to 26% in people with early onset dementia (i.e., <65 years of age) 61. This 261 
subtype is particular common in younger patients (i.e., <45 years: 10% prevalence; 45-64 262 
years: 60% prevalence; >64 years: 30% prevalence). As the disease progresses with duration, 263 
patients develop global cognitive impairment and motor deficits which inevitably lead to death. 264 
Death usually occurs after eight years after symptom onset and is frequently due to pneumonia 265 
or secondary infections 61. 266 
 Some of the clinical symptoms of FTD include progressive deterioration of behaviour 267 
and/or cognition as well as behavioural disinhibition (e.g., socially inappropriate behaviour or 268 
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loss of manners), apathy or inertia, loss of sympathy and empathy (e.g., diminished response 269 
to others’ needs and feelings), stereotyped or compulsive/ritualistic behaviour (e.g., repetitive 270 
movements) or hyperorality and dietary changes (e.g., consumption of inedible objects, altered 271 
food preferences) 62. Due to the similarity of behavioural changes with those seen in psychiatric 272 
disorders, such as compulsive behaviours, delusions and euphoria, diagnosing FTD can be 273 
challenging 61. Also, overlap of symptoms with other neurodegenerative disorders such as AD, 274 
DLB, corticobasal syndrome (CBS) and progressive supranuclear palsy (PSP), renders the 275 
differential diagnosis even more difficult 60. 276 
Vascular dementia (VaD) 277 
 VaD, also known as a single- or multi-infarct dementia, causes around 10% of dementia 278 
cases and develops in around 15-30% of individuals three months after a stroke. 63. Risk factors 279 
for VaD can be divided into four categories: demographic (e.g., age, gender, educational level), 280 
genetic (e.g., ApoE4, familial vascular encephalopathies), atherosclerotic (e.g., hypertension, 281 
smoking, myocardial infarction, diabetes mellitus) and stroke-related (e.g., volume of cerebral 282 
tissue lost, bilateral cerebral infarction, white matter disease) 64. Having one or two ApoE4 283 
alleles has been found to elevate the risk but not to the same extent as in AD 65. 284 
VaD patients can present with different extents of impaired memory and, in contrast to 285 
AD, this criterion of memory disturbance cannot provide an accurate diagnosis. Cognitive 286 
changes also vary significantly, and thus it is thought that the classical mini-mental state 287 
examination (MMSE) may be less efficient for VaD. Another difference from AD is that the 288 
brain pathology is not developing in a predictable pattern and there is still no agreed 289 
pathological scheme to facilitate diagnosis and staging. Trials that have utilised drugs originally 290 
destined for AD have shown that these may not be appropriate for VaD as well 63. The rationale 291 
for trial of cholinesterase inhibitors and memantine (both established for AD) in VaD patients 292 
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was based on evidence of their common features and specifically the cholinergic deficit seen 293 
in VaD. However, it was later suggested that the cholinergic system might not be affected in 294 
VaD alone, but be affected to the same extent as in AD in cases of mixed dementia (i.e., VaD 295 
and AD). Even though there has been substantial progress, VaD is yet under-investigated and 296 
further research is necessary to elucidate the pathologic mechanisms and facilitate treatment 297 
strategies. 298 
Parkinson’s disease dementia (PDD) 299 
 As patients with Parkinson’s disease (PD) progress with time, they often develop a 300 
progressive dementia which is similar to AD and DLB. For PDD, a preceding diagnosis of PD, 301 
before any symptoms of dementia, is necessary; in contrast, when both parkinsonism and 302 
dementia arise in early stages, then DLB is the most likely cause of degeneration 66. The 303 
prevalence of PDD has been estimated to almost 0.2-0.5% in individuals older than 65 years 304 
67, while the incidence rate was found 2.5 per 100,000 person/year for all ages (0-99 years), 305 
which increased to 23 per 100,000 person/year for older individuals (>65 years) 68. 306 
The major pathological feature of PDD is the aggregation of α-synuclein mainly in the 307 
substantia nigra of the brain; these clumps impair dopaminerging nerve cells thus leading to 308 
the characteristic motor and non-motor symptoms of PD 69, 70. Previous work on the clinical 309 
symptoms of PDD has shown that decline in attention, executive functions and visuo-spatial 310 
construction is greater than in AD, whereas verbal and visual memory as well as language 311 
function are less impaired than in AD 71. Also, delusions have been reported to be less common 312 
than AD and DLB, prevalence of depression is thought to be higher than AD, anger and 313 
aggressive behaviour was found more common in AD and sleep quality in PDD and DLB was 314 
poorer than AD and normal controls 71. 315 
Mixed dementia 316 
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Current studies demonstrate that mixed dementia is more common than previously 317 
thought, with pathology resulting from more than one causes. Brain changes result from the 318 
combination of pathological hallmarks of different dementive diseases such as AD, DLB and 319 
VaD 72, 73. 320 
The coexistence of AD and VaD is a very common type of mixed dementia; according 321 
to an autopsy study, 45% AD patients also had cerebrovascular pathology 74. A recent paper 322 
also indicated that in people over 80 years, mixed dementia is the norm, not the exception 63. 323 
It has, thus, been proposed that assessing symptoms by investigating only one pathology may 324 
not apply to older patients who are at-risk from both AD and cerebrovascular disease 9. 325 
Similarly, the majority of DLB cases also have co-existing AD pathology 57, 75. A previous 326 
study has shown that combining different pathologies from AD and LBs (i.e., Aβ, tau and α-327 
synuclein) was a better predictor of PDD than assessing any single pathology 76. 328 
CORRELATION OF DEMENTIA & HEAD INJURY 329 
Emerging evidence demonstrates that traumatic brain injury (TBI), occurring after 330 
repeated head injuries, is one of the risk factors for the development of dementia. Chronic 331 
traumatic encephalopathy (CTE), previously known as dementia pugilistica, is caused by TBI. 332 
The abnormal accumulation of hyperphosphorylated tau protein, along with Aβ plaques, are 333 
the key components in the brains of CTE patients 77 which are also common to other dementia 334 
subtypes, rendering an accurate diagnosis challenging. 335 
It is only after many years of repeated concussive or subconcussive injuries to the head 336 
that an individual eventually goes on to develop CTE 23. This could serve as a time window 337 
and allow for a preclinical, early-phase diagnosis which may subsequently lead to the 338 
development of preventative and therapeutic strategies. Clinical symptoms accompanying CTE 339 
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include memory impairment, behavioural and personality changes, Parkinsonism, and 340 
abnormalities in speech and gait 78. 341 
Previous neuropathological studies have detected CTE in brains of athletes who played 342 
box, rugby, soccer, baseball and ice hockey, as well as in subjects who had experienced a brain 343 
trauma from physical abuse, head-banging or even an explosion in a military combat 77. A very 344 
recent study on 202 deceased football players revealed that 177 of them (87%) had CTE at 345 
biopsy, suggesting that it may be related with their prior participation in football 24. However, 346 
at present, a definitive diagnosis for CTE is only given after neuropathological examination 347 
and therefore, further research is needed for the further understanding and characterisation of 348 
the pathology 77. Investigation is also necessary for the development of neuroimaging and other 349 
biomarkers such as CSF and blood biomarkers. 350 
CURRENT DETECTION METHODS 351 
A definitive diagnosis of dementia can only be given post-mortem after histopathological 352 
examination of the brain tissue. However, a working diagnosis can be provided clinically after 353 
a combination of different neuropsychological tests, brain imaging techniques as well as CSF 354 
and blood testing. Newly discovered biomarkers and techniques have been proposed to 355 
improve the diagnostic accuracy and characterization of dementive diseases (Table 1). 356 
The Mini-Mental State Examination (MMSE) is the most widely used cognitive screening 357 
tool to provide an initial assessment of cognitive impairment, as well as to monitor the 358 
progression of the disease with time 79. The MMSE is in the form of a 30-point questionnaire 359 
with a score less or equal to 24 denoting dementia; it assesses temporal and spatial orientation, 360 
memory as well as language and visuospatial functions. However, it requires the presence of 361 
symptoms and therefore it is not effective with preclinical, asymptomatic cases. Recent studies 362 
have shown that more tests, other than MMSE, should be used as its utility is decreased when 363 
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individuals with MCI and psychiatric conditions are assessed 80, 81. Aside from MMSE, 364 
neurological assessment should be conducted in patients with possible cognitive impairment to 365 
evaluate ataxia, anosmia, involuntary movements, reflexes, visual acuity and other signs 82. For 366 
instance, as AD progresses the patients may develop akinesia, rigidity and myoclonus due to 367 
the extended impairment of cortical and subcortical structures; patients with PDD will present 368 
with bradykinesia, akinetic-rigid symptoms, depression, early visual hallucinations due to 369 
subcortical dysfunctions in the areas of executive function and memory; the initial 370 
presentations of FTD patients include personality change, emotional problems and behavioural 371 
disturbance; in VaD some of the common clinical symptoms include dysarthria, dysphagia, 372 
rigidity, visuospatial deficits, ataxia and pyramidal or extrapyramidal signs; DLB often 373 
involves visual hallucinations, parkinsonism and fluctuating attention and alertness with 374 
intervals of clarity 82. Predisposing family history is also important for a complete assessment. 375 
Even though having a first-degree relative with dementia increases the risk, it does not 376 
necessarily lead to dementia. Other environmental and lifestyle factors have been suggested to 377 
play a significant role as well 83. 378 
Brain imaging techniques, such as magnetic resonance imaging (MRI) and positron 379 
electron tomography (PET), are also widely used in the diagnosis and monitoring of dementias. 380 
Structural MRI can indicate the presence of neurodegeneration by showing the tissue damage 381 
and loss in characteristic regions of the brain such as the hippocampus and other temporal lobe 382 
structures 36. PET imaging techniques can either use 18F-fluorodeoxyglucose (18F-FDG) to 383 
measure the glucose hypometabolism and neurodegeneration, or 11C Pittsburgh compound B 384 
(11C-PiB) to visualise the Aβ plaques 84, 85. Tau PET has been developed to visualise the 385 
regional distribution of tau pathology in vivo using suitable tau-specific tracers. The ability to 386 
investigate the patterns of tau deposition holds great promise for the future as it would facilitate 387 
the segregation between different neurodegenerative diseases, including tauopathies. It has also 388 
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been demonstrated that tau imaging, in contrast to Aβ imaging, is strongly associated with 389 
patterns of neurodegeneration and clinical presentation of AD. It is, however, still in early 390 
stages of development and further research needs to be conducted to validate the sensitivity of 391 
tau PET for age-related tau accumulation 86, 87.  392 
Biological fluids, such as cerebrospinal fluid (CSF) and blood, are increasingly utilised for 393 
the diagnosis, prognosis and monitoring of dementias 88. Three of the main proteins that have 394 
been studied extensively are total tau (T-tau), phosphorylated tau (P-tau) and Aβ42 36, but a 395 
number of other biomarkers have been recently reported to be moderately associated with AD 396 
as well, such as neurofilament light chain (NfL), vinisin-like protein 1 (VLP-1), neuron-397 
specific enolase (NSE), heart fatty acid binding protein (HFABP) and glial activation (YKL-398 
40) 88. T-tau and P-tau have been repeatedly found elevated in patients with AD and are 399 
indicative of neuronal degeneration and accumulation of tau, respectively 85. P-tau is more 400 
specific for AD whereas T-tau can be increased in other brain disorders as well, such as stroke 401 
and brain trauma non-AD dementias 89. As previously mentioned, results have been 402 
controversial among different research groups 90; for instance, Aβ42 level in CSF has been 403 
reported to decrease 85, 88 or increase 91, in comparison to healthy subjects, but was found 404 
unchanged in blood plasma samples 88. Other studies have reported a reduction in plasma Aβ42 405 
in MCI and AD subjects 92 while serum Aβ42 was found unchanged in AD and healthy normals 406 
93. The inconsistent results may occur due to changes in age and timing relative to incident AD 407 
94. A more detailed summary of these biomarkers is given in Table 1. 408 
BIOSPECTROSCOPY AS AN EMERGING DIAGNOSTIC MEANS  409 
Vibrational spectroscopy has been increasingly used in biomedical research to 410 
discriminate and classify normal and pathology. Interrogation of samples with spectroscopic 411 
techniques, and more specifically infrared (IR) and Raman spectroscopy, allows for the 412 
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generation of a “spectral fingerprint” which subsequently facilitates the discrimination of 413 
different populations and identification of potential biomarkers. As previously described, 414 
mixed dementias are now recognised as a highly common phenomenon; with this in mind, we 415 
believe that targeting specific molecules and investigating separate pathological pathways may 416 
not provide a complete picture. On the contrary, with spectroscopy it is feasible to 417 
simultaneously study a range of different biomolecules. Unlike immunological methods, which 418 
detect only one molecule at a time, the spectra obtained from a clinical sample represent a range 419 
of biomolecules such as proteins, lipids and carbohydrates (Figure 6). 420 
Briefly, spectroscopic methods explore the interaction between matter and light; the 421 
biological sample in question (e.g., tissue, CSF, blood) is shone with light of specific 422 
electromagnetic radiation which causes the samples’ molecules to vibrate. These characteristic, 423 
generated movements are then detected and depicted in the form of a spectrum. Spectral peaks 424 
correspond to specific biomolecules and can be used as potential biomarkers for disease. 425 
Further spectral analysis can also allow classification of the diseased and healthy population 426 
and diagnostic values (i.e., sensitivity and specificity) can be determined. 427 
 428 
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Figure 6: The basic principle of biospectroscopy: a source is used to direct radiation to the 429 
clinical sample and cause vibrations to its molecules – spectral information is generated – 430 
spectral analysis allows for classification and biomarker extraction. 431 
  At present, a number of spectroscopic studies have achieved promising results in 432 
diagnosing dementia subtypes and some examples will be presented in this section. Two decades 433 
ago, the first evidence of the structure of Aβ plaques was revealed by IR microspectroscopy 434 
methods after in situ analysis of a section of AD brain 95. This showed that the plaques in the 435 
brain consisted of β-sheet in contrast to the surrounding areas which gave signal of α-helical 436 
and/or unordered conformation.  437 
 Low levels of unsaturated lipids have been suggested to increase the risk or severity of 438 
AD. Using IR imaging, Leskovjan et al., visualised the unsaturated lipid levels in the axonal, 439 
dendritic and somatic layers of the hippocampus of an AD mouse model as a function of plaque 440 
formation 96. As the disease progressed, the lipid unsaturation in the axonal layer was found 441 
significantly lower when compared to normal aging subjects, suggesting that maintenance the 442 
level of unsaturated lipid content may be critical in slowing down the disease. 443 
  A following paper tested 50 AD cases against 14 healthy subjects with both IR and 444 
Raman spectroscopy to account for potential changes in peripheral blood 97. An increased 445 
spectral peak found in AD patients, denoted β-sheet enrichment and was attributed to Aβ peptide 446 
formation. Diagnostic approaches were used to distinguish the patients from the healthy 447 
individuals and achieved an accuracy of ~94%. 448 
Another study analysed both CSF and blood plasma using an immune-IR-sensor to 449 
measure the Aβ peptide secondary distribution 98. The IR-sensor detected a significant 450 
downshift of the Amide I spectral region in patients with AD. The authors concluded that the 451 
shift signalled the transition from a healthy to a dementive status which was depicted in the 452 
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spectra from a transition from α-helical (1652 cm-1) to β-sheet (1627 cm-1) spectral region. The 453 
achieved diagnostic accuracy was 90% for CSF and 84% for blood samples. 454 
Recently, Paraskevaidi et al. published the results of a large-cohort study showing IR 455 
spectroscopy’s ability to discriminate different types of dementia in blood 99. The study 456 
incorporated AD, DLB and FTD as well as other neurodegenerative disorders, such as PD, and 457 
achieved exceptionally high diagnostic accuracy. Distinctive patterns were seen between the 458 
dementia subtypes representing different pathological changes, mostly attributed to proteins 459 
and lipids. The high sensitivity and specificity achieved for distinguishing AD from DLB were 460 
outstanding (90%) and would potentially provide an excellent diagnostic test. A small number 461 
of early-stage AD cases was also included and showed 80% sensitivity and 74% specificity. A 462 
following study by the same group employed Raman spectroscopy achieving equal, and in 463 
some cases even higher, diagnostic accuracies, thus establishing the effectiveness of bio-464 
spectroscopy as a diagnostic tool 100. An additional advantage of Raman spectroscopy over IR 465 
is its ability to analyse aqueous samples which would allow the analysis of fresh samples 466 
without the need of prior dehydration; this would be particularly beneficial for use in a clinic.  467 
The inherently weak signal of spontaneous Raman spectroscopy can be addressed by 468 
employing signal enhancement techniques, such as surface enhanced Raman spectroscopy 469 
(SERS) or coherent anti-Stokes Raman scattering (CARS). A recent review by Devitt et al., 470 
has explored the promise of Raman spectroscopic techniques as an emerging tool to study and 471 
diagnose neurodegenerative disorders 101. A number of diseases have been reviewed in this 472 
paper, namely AD, PD, prion diseases and Huntington’s disease. The cost-effectiveness of 473 
spectroscopy over other expensive and laborious techniques has also been demonstrated, 474 
suggesting its potential for translation into clinic. More studies that have employed 475 
spectroscopy to study different types of dementias and their mechanisms are given in Table 1. 476 
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CONCLUSIONS AND FUTURE PERSPECTIVE 477 
 478 
Improvement of health care and scientific breakthroughs have resulted in increased life 479 
expectancy. Data from the World Health Organization (WHO) have indicated that global 480 
average life expectancy increased by 5 years between 2000-2015, making it the fastest increase 481 
since 1960s; this is estimated to increase by 4 more years by 2030 102. Due to their common 482 
appearance at an older age, neurodegenerative diseases have become a major challenge for 483 
scientific and medical communities. It is now thought that future treatments aiming to delay or 484 
even stop/reverse the disease would be effective if administered at an early stage. Therefore, it 485 
is crucial to develop new techniques and biomarker tests that would allow the detection of 486 
presymptomatic individuals. An on-time diagnosis of patients who are destined to develop the 487 
disease would allow them to enroll in clinical trials with the hope that this would prevent the 488 
disease. 489 
 Another important consideration is that the affected persons and their families need to 490 
be adequately informed about the disease characteristics, symptoms, prognosis, available 491 
treatments and ongoing clinical trials so that they can plan their future, develop strategies and 492 
seek healthcare assistance if necessary. 493 
A more reliable, affordable and less-invasive test is an unmet need in the field of 494 
neurodegeneration. Despite the significant advancement in deciphering the underlying 495 
pathology and mechanisms, these diseases remain incurable. Much effort has been put into 496 
alternative methodologies such as spectroscopic methods, which provide a panel of different 497 
biomolecules, rather than focusing on specific molecules, such as Aβ and tau proteins. 498 
Biospectroscopy can be a label-free, non-destructive and inexpensive method and it has shown 499 
potential as a means for diagnosing and/or monitoring disease progression. Surely, as with 500 
every novel method or biomarker, additional research is needed for the repetition and validation 501 
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of current studies in larger cohorts and from different research groups. The new knowledge 502 
acquired could then be incorporated into the diagnostic criteria and guidelines. Minimally 503 
invasive sampling, such as in blood plasma and serum, are gaining increasing attention as 504 
biomarkers in neurodegenerative diseases. Changes in the blood are often subtle and may 505 
reflect a range of peripheral and central processes; however, with increasing age the blood-506 
brain barrier is disrupted and it has also been found that 500 ml of CSF is daily discharged into 507 
the bloodstream which renders it an information-rich sample 103, 104. 508 
To summarise, there has been a great advancement in the understanding of the complex 509 
neurodegenerative processes. World-leading experts are now confident that we are 510 
approaching a major breakthrough in the field of dementia which could potentially improve 511 
patients’ lives by alleviating or even curing the devastating symptoms of the condition. There 512 
is also a strong consensus that a definitive and early diagnosis would more likely be given after 513 
a combination of different biomarkers and analytical methods, rather than a focus on traditional 514 
approaches; perhaps an unconventional and “fresh” look on the problem is the key for a turning 515 
point in dementia research. Increasing research funding is also a very important factor that has 516 
to be secured in order to accelerate the pace of progress and continuous efforts should be made 517 
to maintain this. 518 
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            Table 1: Biomarkers for the diagnosis of dementia subtypes.  977 
Study Technique 
Type of 
Dementia 
Sample Outcome/Accuracy 
Imaging Tests 
Frisoni, 2017 85 MRI AD 
In vivo 
imaging 
Decreased volume of hippocampus 
& temporal lobe structures due to 
tissue loss & neurodegeneration 
 18FDG-PET AD 
In vivo 
imaging 
Decreased uptake due to glucose 
hypometabolism & 
neurodegeneration 
 Amyloid PET AD 
In vivo 
imaging 
Increased binding due to Aβ in the 
cortex 
Saint-Aubert, 2017 105 Tau PET 
AD, FTLD, 
DLB 
In vivo 
imaging 
In contrast to Aβ plaques, tau protein 
aggregates primarily intracellularly 
rendering it difficult to access in 
vivo. Novel (~5 yrs) tau PET tracers 
show promise for the discrimination 
between neurodegenerative diseases 
and monitoring of disease 
progression; more research is 
required as, despite promising, it has 
been suggested that the tracer might 
not bind substantially to the tau 
burden 
McKeith, 2017 6 SPECT/PET  AD, DLB 
In vivo 
imaging 
Reduced DAT uptake in basal 
ganglia  provided 78% sensitivity 
and 90% specificity 
 
123Iodine-
MIBG 
scintigraphy 
AD, DLB 
In vivo 
imaging 
Reduced uptake on MIBG 
myocardial scintigraphy was 
reported in LB disease; sens (69%) 
and specif (87%) values that 
discriminated between probable DLB 
and AD, increased to 77% and 94% 
in milder cases 
 CT/MRI  AD, DLB 
In vivo 
imaging 
Relative preservation of medial 
temporal lobe (MTL) structures on 
CT/MRI scan; in contrast to AD, 
DLB patients do not show a great 
atrophy of MTL; 64% sens and 68% 
specif were the values for separating 
AD from DLB 
 Amyloid PET AD, DLB 
In vivo 
imaging 
Increased Aβ deposition in >50% 
DLB patients; limited value in 
differentiating from AD; combining 
biomarkers could improve 
differential diagnosis 
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 Tau PET AD, DLB 
In vivo 
imaging 
Tau PET imaging, along with MTL 
atrophy, may indicate coexisting AD 
pathology in DLB 
Ossenkoppele, 2016 87 
Tau, Aβ and  
18FDG PET 
AD 
In vivo 
imaging 
Tau imaging, in contrast to Aβ, 
showed a strong regional association 
with clinical and anatomical 
heterogeneity in AD; results from a 
novel PET tracer were promising but 
still preliminary, requiring further 
research 
Beach, 2014 106 Amyloid PET AD 
In vivo 
imaging 
The diagnostic accuracy of a positive 
Aβ scan was estimated at between 
69%-95% sens and 83%-89% specif. 
Richard, 2013 107 MRI MCI 
In vivo 
imaging 
After administration of a short 
memory test, the added improvement 
in classification, coming from an 
MRI, was only +1.1%, showing it 
does not substantially affect the 
diagnostic accuracy for predicting 
progression in MCI patients; the 
study highlights the importance of 
the order of different tests when 
assessing cognitive complaints 
Frisoni, 2010 36 MRI AD 
In vivo 
imaging 
Atrophy of medial temporal 
structures is a valid biomarker of AD 
and its progression; MRI is also a 
partially validated candidate marker 
for MCI and non-AD dementias 
McKeith, 2005 58 MRI DLB 
In vivo 
imaging 
Preserved medial temporal lobes 
(relative to AD) 
Neary, 1998 108 MRI FTLD 
In vivo 
imaging 
Focal frontal or temporal atrophy 
Roman, 1993 109 MRI VaD 
In vivo 
imaging 
Strategic infarct or extensive white 
matter changes 
Biomarker Tests 
Frisoni, 2017 85 Proteomics AD CSF 
Decreased Aβ42 or Aβ42:Aβ40 ratio 
due to abnormal Aβ metabolism; 
increased T-tau and P-tau due to 
neuronal damage and accumulation 
of tau 
Mattsson, 2017 110 Proteomics AD, MCI 
CSF & 
Blood 
Plasma 
Plasma NFL was correlated with 
CSF NFL and was increased in MCI 
and AD when compared to HC; high 
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NFL levels were correlated with poor 
cognition and AD-related atrophy; 
diagnostic accuracy was 87%; 
however, plasma NFL levels are 
increased in other neurological 
disorders too and thus, could not be 
used for differential diagnosis of AD 
McKeith, 2017 6 Proteomics DLB 
CSF, blood, 
peripheral 
tissue 
Biomarkers for DLB are elusive and 
the understanding of the core 
biomarkers remains limited; CSF α-
synuclein is not yet proven as a 
biomarker, while Αβ and tau may be 
more useful in detecting coexisting 
AD 
Tatebe, 2017 111 Proteomics AD, VaD 
Blood 
Plasma 
Plasma levels of P-tau181 were 
significantly higher in AD than in 
HC, providing 60% sens and 86% 
specif; P-tau181 levels in AD and 
VaD were significantly correlated 
with those in CSF; further study was 
suggested to validate the preliminary 
results 
Olsson, 2016 88 Proteomics AD 
CSF & 
Blood 
serum/plasm
a 
The core CSF biomarkers for 
neurodegeneration (T-tau, P-tau and 
Aβ42), CSF NFL and plasma T-tau 
were associated with AD; the core 
biomarkers were strongly associated 
with MCI due to AD; promising CSF 
biomarkers also included NSE, VLP-
1, HFBP and YKL-40; plasma Aβ42 
and Aβ40 were not strongly 
associated with AD 
Wolters, 2016 112 Proteomics AD Blood Serum 
APOE associated with long-term risk 
of AD in general population; 
additional value was limited 
Forlenza, 2015 113 Proteomics AD CSF 
Aβ42 levels showed 89% sens and 
70% specif; T-tau levels showed 
82% sens and 67% specif; P-tau 
levels showed 83% sens and 49% 
specif; Aβ42:P-tau ratio showed 88% 
sens and 78% specif; Aβ42:T-tau 
ratio showed 80% sens and 80% 
specif; combining Aβ42 and Aβ42:P-
tau ratio was able to predict the 
conversion in 2 yrs 
González-Domínguez, 
2015 114 
Metabolomics AD Blood Serum 
Alterations in the levels of 23 
metabolites were detected in AD 
patients; metabolic pathway analysis 
showed different impairments such 
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as hypometabolism, oxidative stress, 
hyperammonemia and others 
Hye, 2014 115 Proteomics AD, MCI 
Blood 
Plasma 
Sixteen proteins correlated with 
disease severity and cognitive 
decline; strongest associations were 
in the MCI group with a panel of 10 
proteins predicting progression to 
AD with 85% sens and 88% specif 
Mapstone, 2014 116 Lipidomics AD 
Blood 
Plasma 
In a 5-yr observational study, a panel 
of ten lipids was shown to predict 
phenoconversion to either amnestic 
MCI or AD within a 2-3 yr. 
timeframe; accuracy was found 90% 
Chiu, 2013 117 Proteomics AD, MCI 
Blood 
Plasma 
Aβ42 and tau protein are significantly 
lower in the HC group; 
differentiation of MCI from AD was 
achieved with ~90% accuracy; 
combined biomarkers differentiate 
HC from MCI and AD 
Trushina, 2013 118 Metabolomics AD, MCI 
CSF & 
Blood 
Plasma 
Researchers found 23 altered 
pathways in plasma and 20 in CSF 
after the comparison of MCI versus 
HC; the number of affected pathways 
increased with disease severity; 
affected pathways included energy 
metabolism, mitochondrial function, 
lipid biosynthesis and others; data 
from this study suggested that 
metabolomics could reveal early 
disease mechanisms shared in 
progression from HC to MCI and 
AD 
Richard, 2013 107 Proteomics MCI CSF 
After administration of a short 
memory test, the added improvement 
in classification, coming from a CSF 
test (P-tau:Aβ ratio), was -2.2%, 
showing it does not improve the 
diagnostic accuracy for predicting 
progression in MCI patients; the 
study highlights the importance of 
the order of different tests when 
assessing cognitive complaints 
Zetterberg, 2013 119 Proteomics AD, MCI 
CSF & 
Blood 
Plasma 
Tau levels in AD plasma were 
increased when compared to MCI 
and HC but with overlapping ranges 
across the groups which diminishes 
its utility as a diagnostic test; there 
was also no correlation between 
plasma tau and CSF tau which may 
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be due to its clearance from the 
bloodstream (within 24 hrs) 
Blennow, 2010 120 Proteomics AD 
CSF & 
Blood 
Plasma 
CSF Aβ42 level is reduced in AD and 
prodromal AD; CSF P-tau and T-tau 
levels are increased in AD and 
prodromal AD and are indicative of 
tau phosphorylation and neuronal 
degeneration, respectively; a panel of 
18 plasma proteins has been reported 
to diagnose & predict AD in MCI; 
contradictory results in plasma Aβ42 
or Aβ40 may reflect that peripheral 
plasma does not reflect Aβ 
metabolism; plasma levels of 
complement factor H (CFH) and 
alpha-2-macroglobulin (A2M) were 
increased in AD 
Cedazo-Minguez, 2010 40 Proteomics AD 
Blood 
Plasma 
Plasma total Aβ or Aβ42 levels were 
found increased in familial AD but 
the results were not consistent in 
sporadic AD; elevated Aβ42 levels, 
low levels of Aβ42 or a reduced Aβ42/ 
Aβ40  ratio may indicate the 
conversion from HC to MCI or AD 
Lui, 2010 92 Proteomics AD 
Blood 
Plasma 
Lower Aβ42:Aβ40 ratio in AD; Aβ42 
reduction in MCI and AD 
Brys, 2009 121 Proteomics AD, MCI CSF 
P-tau231 was the strongest predictor 
of the decline from MCI to AD; 
isoprostane levels showed 
longitudinal progression effects 
Lambert, 2009 122 Genomics AD 
DNA 
samples 
Markers with suggestive evidence of 
association with AD, apart from 
APOE, were examined; two loci 
gave replicated evidence: one within 
CLU (or else APOJ) on chromosome 
8 and the other within CR1 on 
chromosome 1; CLU and CR1 are 
involved in the clearance of Aβ 
Lopez, 2009 123 Proteomics AD 
Blood 
Plasma 
Plasma levels of Aβ40 and Aβ42 were 
not associated with incident AD after 
adjustment for age and vascular risk 
factors; Aβ not useful as a biomarker 
Roher, 2009 124 Proteomics AD 
Blood 
Plasma, 
Platelets & 
Peripheral 
Tissues 
Plasma Aβ fluctuated over time and 
among individuals, failing as a 
biomarker; substantially higher Aβ 
was found in liver tissue from AD; 
brain & skeletal muscle has elevated 
Aβ 
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Bian, 2008 125 Proteomics AD, FTLD CSF 
T-tau and T-tau:Aβ42 levels were 
significantly lower in FTLD than in 
AD; T-tau:Aβ42 ratio was a sensitive 
biomarker distinguishing FTLD from 
AD with 79% sens and 97% specif 
Blasko, 2008 126 Proteomics AD, MCI 
Blood 
Plasma 
Plasma levels of Aβ42 alone is not a 
suitable biomarker for predicting 
AD; Aβ42 increase seems to be an 
initial event in AD and changes in 
the levels may reflect a transition 
from HC/MCI to AD. HC to MCI 
converters were found with ~60% 
sens/specif, while HC to AD 
converters with ~50% sens and 63% 
specif   
Schupf, 2008 127 Proteomics AD 
Blood 
Plasma 
Higher Aβ42 levels at the onset of this 
4.6 yr follow-up study, were 
associated with a threefold increased 
risk of AD; conversion to AD was 
accompanied by a decline in Aβ42 
and Aβ42:Aβ40 ratio which may 
indicate compartmentalization of Aβ 
in the brain 
Sundelof, 2008 94 Proteomic 
AD, VaD, 
FTD, PDD 
Blood 
Plasma 
Low Aβ40 levels predicted incident 
AD in elderly men (77 yrs); Aβ42 was 
not significantly associated with AD; 
high ratio of Aβ42:Aβ40 was 
associated with VaD risk 
Abdullah, 2007 93 Proteomics AD 
Blood Serum 
& Plasma 
AD patients had significantly higher 
Aβ40 but no difference in Aβ42 levels; 
serum Aβ42:Aβ40 ratio was lower in 
AD 
Ewers, 2007 128 Proteomics AD, MCI CSF 
Levels of Aβ42 are decreased in AD 
and MCI, while levels of T-tau and 
P-tau are increased; P-tau levels were 
a significant predictor of conversion 
from MCI to AD, independent of 
age, gender, MMSE and APOE 
genotype 
Graff-Radford, 2007 129 Proteomics AD, MCI 
Blood 
Plasma 
Aβ42:Aβ40 ratio may be a useful 
premorbid biomarker for cognitive 
normal individuals who are at risk of 
MCI or AD; subject with lower 
Aβ42:Aβ40 levels showed 
significantly higher risk for MCI or 
AD and had greater cognitive decline 
Hansson, 2006 130 Proteomics AD, MCI CSF 
CSF concentrations of T-tau, P-tau181 
and Aβ42 were strongly associated 
with future development of AD in 
MCI patients; combination of T-tau 
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and Aβ42 yielded 95% sens and 83% 
specif for detection of incipient AD 
in MCI; combination of T-tau and 
Aβ42/P-tau181 yielded 95% sens and 
87% specif 
Pesaresi, 2006 131 Proteomics AD, MCI 
Blood 
Plasma 
Reduction of plasma Aβ42 as marker 
for AD, specifically a transition from 
HC/MCI to AD 
van Oijen, 2006 132 Proteomics AD, VaD 
Blood 
Plasma 
High concentrations of Aβ40 along 
with low concentrations of Aβ42 
showed increased risk of dementia; 
increased Aβ42:Aβ40 ratio showed 
reduced risk of dementia; 
associations were similar for AD and 
VaD 
Rüetschi, 2005 133 Proteomics FTD CSF 
Forty-two protein peaks were 
differentially expressed in FTD in 
comparison to non-demented 
controls; ten peaks were selected, 
five of which were increased and 
five decreased, allowing sens of 94% 
and specif of 83% 
Sobow, 2005 134 Proteomics AD, MCI 
Blood 
Plasma 
Plasma levels of Aβ42 were higher in 
MCI in comparison to HC and AD; 
Aβ40 did not differ between the 
groups; Aβ would not allow an 
accurate differential diagnosis of AD 
but might be useful for MCI patients 
(~95% sens and ~75% specif) 
Assini, 2004 135 Proteomics MCI 
Blood 
Plasma 
Levels of Aβ42 were slightly higher 
in MCI than in HC but did not reach 
significance; when grouped for sex, 
women with MCI had increased 
Aβ42; no significant sex-related were 
found for Aβ40  
Hampel, 2004 136 Proteomics 
AD, MCI, 
VaD, FTD, 
DLB 
CSF 
P-tau181 differentiated AD and DLB, 
whereas P-tau231 differentiated AD 
and FTD; P-tau396/404 was a 
promising biomarker to differentiate 
AD and VaD; high P-tau231 levels 
may indicate progressive cognitive 
decline in MCI subjects 
Fukumoto, 2003 137 Proteomics AD 
Blood 
Plasma 
Plasma Aβ levels increased 
significantly with age but were 
correlated to age rather than 
diagnosis, medication or APOE 
genotype, thus Aβ is not sensitive or 
specific biomarker of AD or MCI 
Zetterberg, 2003 138 Proteomics AD, MCI CSF 
Combination of three CSF 
biomarkers (T-tau, P-tau, Aβ42) can 
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detect early AD among patients with 
MCI with 68% sens and 97% specif 
Mehta, 2000 139 Proteomics AD 
CSF & 
Blood 
Plasma 
Plasma Aβ40 elevated in AD but not 
useful to support the clinical 
diagnosis due to considerable 
overlap; plasma Aβ42 similar between 
AD and HC; CSF Aβ40 similar 
between AD and HC; CSF Aβ42 
lower in AD 
Vanderstichele, 2000 140 Proteomics AD, DLB 
CSF, Urine, 
Blood Serum 
& Plasma  
Aβ42 in serum and urine were below 
detection limit; in plasma no Aβ42 
differences were seen between HC 
and patients; CSF Aβ42 was lower in 
AD and DLB suggesting it as a 
useful biomarker 
Andreasen, 1999 141 Proteomics AD CSF 
Decreased Aβ42 levels were could 
serve as diagnostic biomarker in AD 
(92% sens); no significant 
correlations between CSF Aβ42 level 
and duration or severity 
Kanai, 1998 142 Proteomics AD CSF 
Significant elevation of tau levels 
and Aβ40:Aβ42 ratio, as well as 
decrease of Aβ42 levels, were 
observed in AD patients; the assays 
provided ~70% sens. and 83% 
specif. 
Motter, 1995 143 Proteomics AD CSF 
Aβ42 levels were found significantly 
lower in AD while total Aβ levels 
were not, suggesting that diminished 
Aβ42 clearance may account for its 
reduction in CSF; tau levels were 
increased in AD 
Spectroscopic Tests 
Huang, 2017 144 
Raman 
spectroscopy 
AD 
Brain Tissue, 
Blood Serum 
& Plasma 
Biomarkers of AD, such as Aβ and 
tau proteins or the neurotransmitters 
involved in AD (e.g., glutamate and 
γ-aminobutyric acid),  have been 
identified to distinguish patients 
from HC individuals 
Michael, 2017 145 
Raman 
Spectroscopy 
AD Brain Tissue 
Tissue imaging identified plaques 
and tangles in unstained, label-free 
brain tissue; two times more proteins 
and five times more β-sheets were 
found inside the plaque- and tangle-
like features, as compared to the 
surrounding tissue 
Paraskevaidi, 2017 99 
ATR-FTIR 
Spectroscopy 
AD, DLB, 
FTD 
Blood 
Plasma 
AD patients were detected with 86% 
sens and specif when individuals had 
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one or two alleles of APOE ε4, while 
in individuals with no ε4 alleles 
diagnostic accuracy was lower at 
72% sens and 77 specif; early AD 
cases were distinguished with 80% 
sens and 74% specif; differences 
coming with AD duration were also 
noted; AD was also distinguished 
from DLB with 90% sens and specif; 
FTD was also segregated from HC 
Paraskevaidi, 2017 
Raman 
Spectroscopy 
AD, DLB 
Blood 
Plasma 
Early-stage AD was detected with 
84% sens and 86% specif; late-stage 
AD was detected with 84% sens and 
77% specific; DLB was detected 
with 83% sens and 87% specif; late-
stage AD was distinguished from 
DLB with 90% sens and 93% specif; 
wavenumbers assigned to specific 
biomolecules were also suggested as 
a panel of biomarkers 
Mordechai, 2017 146 
FTIR 
Spectroscopy 
AD 
Blood 
Plasma & 
White Blood 
Cells 
Mild, moderate and severe cases of 
AD were distinguished from HC 
individuals with 85% accuracy when 
using white blood cells and ~77% 
when using blood plasma 
Nabers, 2016 98 
FTIR 
Spectroscopy 
AD 
CSF & 
Blood 
Plasma 
Employing an immune-IR-sensor, 
there was a discrimination between 
AD and HC with a 90% accuracy in 
CSF and 84% in blood plasma; a 
significant downshift, indicative of 
the overall β-sheet structure, was 
noted in the AD patients 
Kiskis, 2015 147 CARS AD Brain Tissue 
Enhanced Raman imaging of tissue 
sections from the prefrontal cortex 
showed evidence of lipid deposits 
co-localizing with Aβ plaques 
Demeritte, 2015 148 SERS AD Whole Blood 
Antibody-coated nanoparticles were 
used to enhance the Raman signal; 
Aβ and tau proteins were both 
detected in concentrations as low as 
100 fg/mL level; the spectroscopic 
technique showed advantages over 
ELISA detecting Aβ (0.312 ng/mL) 
and tau (0.15 ng/mL) 
Ryzhikova, 2015 149 
Raman 
Spectroscopy 
AD, DLB, 
FTD 
Blood Serum 
Patients with AD were differentiated 
from HC and other dementias with 
~95% sens and specif 
Carmona, 2015 97 
Raman and IR 
Spectroscopy 
AD 
Blood 
Plasma 
Patients with AD and age-matched 
healthy controls were distinguished 
with a diagnostic accuracy of ~94% 
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Magierski, 2014 150 
Magnetic 
Resonance 
Spectroscopy 
AD, DLB 
In vivo Brain 
Tissue 
Imaging 
Proton magnetic resonance 
spectroscopy has been demonstrated 
as a noninvasive method to assess 
the biochemistry of brain tissue in 
vivo 
Carmona, 2013 151 
Raman and IR 
Spectroscopy 
AD 
Blood 
Plasma 
Spectral biomarkers were identified 
in the Raman and IR region and were 
indicative of protein secondary 
structure, protein α-helices, protein 
tertiary structure and oxidative 
stress; the diagnostic accuracy 
achieved 89% sens and 92% specif 
Luo, 2013 152 
Raman 
Spectroscopy 
AD Platelets 
Early and differential (from PD) 
diagnosis of AD was demonstrated; 
80% sens. for 12-month AD, 75% 
sens. for 4-month AD and 100% 
specif. were achieved 
Chen, 2011 153 
Raman 
Spectroscopy 
AD, VaD Platelets 
Early and differential diagnosis of 
AD from VaD; two peaks (740 cm-1: 
protein side chain vibration and 1654 
cm-1: Amide I of the protein α-helix 
structure 154) were mostly 
responsible for the segregation 
between HC and AD  
Leskovjan, 2010 96 
FTIR 
Spectroscopy 
AD Brain Tissue 
FTIR imaging was used to visualize 
the unsaturated lipid content in 
specific regions of the hippocampus 
in an AD mouse model as a function 
of plaque formation; the unsaturated 
lipid content was reduced in the 
hippocampal white matter during Aβ 
pathogenesis 
Burns, 2009 155 
NIR 
Spectroscopy 
AD 
Blood 
Plasma 
Five spectral bands corresponding to 
heme, R-CH, R-OH, H2O and R-NH 
were used to distinguish between AD 
and HC with 80% sens and 77% 
specif; spectra were not influenced 
by age, gender, exposure to 
cholinesterase inhibitors or sample 
storage time 
Chen, 2009 156 
Raman 
Spectroscopy 
AD 
Brain 
Hippocampu
s Tissue 
In situ Raman analysis distinguished 
AD from normal tissue; biochemical 
changes that were observed included 
the increase of Aβ protein, 
cholesterols and 
hyperphosphorylated tau 
Peuchant, 2008 157 
FTIR 
Spectroscopy 
AD 
Blood 
Plasma 
A clear separation was achieved 
between AD and HC by using a 
restricted spectral range; changes 
were related to modified lipid and 
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nucleic acid structures involved in 
oxidative stress processes of AD; the 
diagnostic accuracy was ~98% 
Kantarci, 2004 158 
Magnetic 
Resonance 
Spectroscopy 
AD, VaD, 
DLB, FTLD 
In vivo Brain 
Tissue 
Imaging 
Metabolite ratio changes were 
evaluated and shown as useful 
imaging markers in common 
dementias; N-
Acetylaspartate/creatine levels were 
decreased in dementias that undergo 
neuron loss such as AD, FTLD and 
VaD; myoinositol/creatine were 
elevated in dementias pathologically 
characterized by gliosis such as AD 
and FTLD; choline/creatine was 
increased in dementias with a 
profound cholinergic deficit such as 
AD and DLB 
Choo, 1996 95 
FTIR 
Spectroscopy 
AD Brain tissue 
The structure of Aβ protein within a 
slice of human AD brain tissue was 
reported for the first time; protein in 
grey matter existed predominantly in 
an α-helical and/or unordered 
conformation, whereas within 
amyloid deposits a beta-sheet 
structure predominated 
 978 
Abbreviations: Aβ: amyloid beta; AD: Alzheimer’s disease; APOE: apolipoprotein; APOJ: 979 
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